Dispensing for the biologic agent secukinumab was inequitable during the period it was funded only for severe psoriasis (October 2018 to April 2021), according to a study analysing Ministry of Health data. Individuals in the least socioeconomically deprived areas were more likely to receive secukinumab than those in the most socioeconomically deprived areas, with dispensing rates of 6.56 (95% confidence interval [CI] 5.61-7.51) and 4.00 (95% CI 3.29-4.71) per 100,000 population, respectively (p<0.0001). Māori, Pacific and Asian peoples were less likely to receive secukinumab, with dispensing rates of 3.27 (95% CI 2.56-3.99), 3.31 (95% CI 2.28-4.33) and 4.33 (95% CI 3.48-5.19), respectively, compared with a dispensing rate of 6.30 (95% CI 5.81-6.79) in European peoples (p<0.0001).